Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $60.08M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.60M
Balance Sheet
Inspect the capital base behind the business.
Assets
$129.72M
FY 2025 · Annual
-34.0% YoYLiabilities
$17.20M
FY 2025 · Annual
-13.1% YoYEquity
$112.52M
FY 2025 · Annual
-36.4% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 99.6M | 29.52M | 36.02M | 39.82M | 41.5M |
| Short-term Investments | 0 | 98.23M | 91.44M | 139.66M | 77.08M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.34M | 2.23M | 2.15M | 1.86M |
| Total Current Assets | 100.41M | 132.1M | 129.69M | 181.63M | 120.45M |
| Property, Plant & Equipment (Net) | 5.79M | 6.86M | 7.91M | 8.03M | 7.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 41.88M | 0 | 5.09M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 388K | 388K | 665K | 1.85M | 1.86M |
| Total Non-current Assets | 6.18M | 49.13M | 8.57M | 14.96M | 9.27M |
| Total Assets | 106.59M | 181.23M | 138.27M | 196.59M | 129.72M |
| Account Payables | 964K | 904K | 5.05M | 758K | 2.28M |
| Short-term Debt | 0 | 0 | 0 | 1.06M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 66K | 69K | 0 | 0 | 0 |
| Other Current Liabilities | 667K | 2.66M | 3.86M | 5.46M | 5.56M |
| Total Current Liabilities | 2.91M | 6.52M | 13.3M | 17.21M | 15.66M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 122.52M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 127.48M | 4.24M | 3.77M | 2.59M | 1.54M |
| Total Liabilities | 130.4M | 10.75M | 17.07M | 19.8M | 17.2M |
| Common Stock | 2K | 22K | 23K | 31K | 31K |
| Retained Earnings | (24.87M) | (56.03M) | (116.42M) | (196.98M) | (274.88M) |
| Accumulated OCI | 0 | (95K) | (83K) | 447K | 111K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (23.81M) | 170.48M | 121.2M | 176.79M | 112.52M |
| Total Debt | 5.63M | 4.96M | 4.64M | 3.65M | 2.71M |
| Net Debt | (93.98M) | (24.56M) | (31.37M) | (36.17M) | (38.79M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $34.1M |
| Short-term Investments | $63.7M |
| Other Current | $1.5M |
| Total Current Assets | $99.2M |
| PP&E (Net) | $6.9M |
| Other Non-current | $1.7M |
| Total Non-current Assets | $8.6M |
| Total Assets | $107.8M |
Analysis
Selected assets total $107.8M for Latest. The largest visible component is Short-term Investments at $63.7M, about 59.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 |
How much cash does ACRV have?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported $41.50M in cash and equivalents in fiscal 2025.
How much debt does ACRV carry?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported $2.71M of total debt, with net debt of -$38.79M.
Continue the stock analysis
Jump to another research area for this company.